Showing 6161-6170 of 7674 results for "".
- FDA Grants Breakthrough Device Status to Alpha DaRT for SCChttps://practicaldermatology.com/news/fda-grants-breakthrough-device-status-to-alpha-dart-for-scc/2460829/The U.S. Food and Drug Administration (FDA) granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma (SCC) of the skin and oral cavity without curative standard of care. Alpha Tau submitted data to the FDA supporting this de
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Trem
- Sofwave Medical Goes Public on the Tel Aviv Stock Exchangehttps://practicaldermatology.com/news/sofwave-medical-goes-public-on-the-tel-aviv-stock-exchange/2460824/Sofwave Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE) and raised $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters. The company has developed Synchronous Ul
- AstraZeneca's Anifrolumab Shows Benefit for Skin, Joint Symptoms of Lupushttps://practicaldermatology.com/news/astrazenecas-anifrolumab-shows-benefit-for-skin-joint-symptoms-of-lupus/2460819/Anifrolumab is consistently associated with improvements in both skin rash and arthritis across three different disease measures in patients with moderate to severe systemic lupus erythematosus (SLE), results of a new post-hoc analysis of pooled data from the TULIP phase 3 clinical trials show. T
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers/2460816/Henry H.L. Chan, MD, PhD, FRCP, is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Chan is currently the Honorary Clinical Professor and Honorary Consultant Dermatologist of the Division of Dermatology, Department of Medicine, The University of Hong
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- Meet PDO Max's New Executive Hireshttps://practicaldermatology.com/news/meet-pdo-maxs-new-executive-hires/2460810/Dina BenDavid is the new Director of Training and Clinical Development at PDO Max. BenDavid is a board-certified nurse practitioner, holds both a Master's and Doctoral degrees, and is a professor of nursing and clinical trainer in medical aesthetics. She is founder and owner of
- Medivir’s Remetinostat Shows Promise for SCChttps://practicaldermatology.com/news/medivirs-remetinostat-shows-promise-for-scc/2460807/Topical remetinostat gel performed well in a small investigator-initiated phase II clinical study of patients with squamous cell carcinoma. Four patients with five cutaneous SCCs were included in this case series and treated with remetinostat gel 1%. All five tumors, including
- Abbvie’s JAK1 Inhibitor Measures Up in Two Phase 3 Studies of ADhttps://practicaldermatology.com/news/abbvies-jak1-inhibitor-measures-up-in-two-phase-3-studies-of-ad/2460806/Upadacitinib yields rapid and significant improvements in patients with moderate to severe atopic dermatitis, according to results from two phase 3 clinical trials published online in The Lancet. Patients who received upadacitinib showed reductions in all clinical disease meas
- It's a RAP: Allergan Set to Acquire Solitonhttps://practicaldermatology.com/news/deal-time-allergan-set-to-acquire-soliton/2460801/Allergan Aesthetics is set to acquire Soliton and Resonic, its Rapid Acoustic Pulse device. Resonic recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The ac